5324882026-04-012026-06-305324882026-04-012026-06-30in-capmkt:OtherExpenses1Member5324882026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares532488DIVISLABNOTLISTEDINE361B01024Divi's Laboratories LimitedMain BoardEquity2026-04-012027-03-312026-08-012026-07-20INRCroresQuarterlyFirst quarterSingle segmentManufacture of Active Pharmaceutical Ingredients, Intermediates and Nutraceutical Ingredients.2026-08-0110:15:002026-08-0111:20:00Not applicablefalsefalseThere are no default on loans and debt securities2026-04-012026-06-30UnauditedStandalone2974000000063000000030370000000149500000000-56700000003970000000600000001320000000409000000018720000000116500000000116500000002900000000-16000000027400000000891000000000008910000000100000008920000000530000000233.5533.550033.5533.551.The above Statement of standalone unaudited financial results for the quarter ended 30th June, 2026 (Standalone statement) is prepared in accordance with the recognition and measurement principles laid down in applicable Indian Accounting Standards(Ind AS), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The Standalone statement has been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on August 01, 2026. The statutory auditors have carried out a limited review of the Standalone statement and issued an unmodified report thereon. <br /> <br /> 2.The Company is engaged in the manufacture of Active Pharmaceutical Ingredients, Intermediates and Nutraceutical Ingredients and the same constitutes a single reportable business segment as per Ind AS 108. <br /> <br /> 3.The Company does not have any discontinued operations and the profit for the period represents profits from continuing operations only. <br /> <br /> 4.Financial results for the quarter ended 31.03.2026 are the balancing figures between audited figures in respect of full financial year and the unaudited published year to date figures up to the third quarter of the respective financial year, which were subjected to limited review. <br /> <br /> 5. Details of Forex gain/(loss) are as given below: ( in Crores) <br /> Quarter Ended Year Ended <br /> 30.06.2026 31.03.2026 30.06.2025 31.03.2026 <br /> <br /> Forex gain/(loss) (7) 89 39 210 <br /> <br /> Forex gain has been included in other income and loss has been included in other expenses. <br /> Other Expenses4090000000Gain/(Loss) on Remeasurement of post-employment benefit obligations20000000200000001000000010000000